Hot Warren Buffett Stocks For 2017

Warren Buffett has remained quiet, despite being the largest Wells Fargo (NYSE:WFC) shareholder. Why so quiet? I feel he likely doesn’t agree with WFC’s practices (or doesn’t care), but what’s he really to do? He can’t sell, and buying isn’t a sound idea – this isn’t a generational buying opportunity for WFC.

Click to enlarge

Buffett won’t be riding to the rescue of anything soon, but there’s only a handful of companies with large enough market caps that he can invest in these days. At the same time, Buffett has been taken to task in the past over his ethical decisions (read: a large investment in sugary drink maker Coca-Cola (NYSE:KO), his trailer park business, the Sokol-Lubrizol days, etc.)

In trading on Thursday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 5 percent, and Consolidated Water Co. Ltd. (NASDAQ: CWCO), down 2 percent.

[By Lisa Levin]

In trading on Tuesday, utilities shares fell by 0.58 percent. Meanwhile, top losers in the sector included Middlesex Water Company (NASDAQ: MSEX), down 2 percent, and Genie Energy Ltd (NYSE: GNE), down 4 percent.

Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

Agence France-Presse/Getty Images

The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…

Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.

Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.

Shares of Clayton Williams Energy, Inc. (NYSE: CWEI) got a boost, shooting up 28 percent to $94.93 after the company announced an agreement to sell Giddings Area assets for $400 million and named Patrick Cooke as COO.

While some of these stocks have performed well, we arent recommending this list of natural gas stocks. Thats because we arent interested in stocks that have already peaked at Money Morning; were interested in the next big winner. And we have one that could surge in 2017

[By Ben Levisohn]

Noble Energy (NBL) soared to the top of the S&P 500 today after purchasing Clayton Williams Energy (CWEI) for $2.7 billion.

“The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”

In its first full year as a publicly traded company, online dating conglomerateMatch Group (NASDAQ:MTCH) surged past expectations, climbing 26%.

A number of factors led to its standout performance, including blockbuster growth from Tinder, strong operating leverage, and consistently beaten earnings estimates. Let’s take a closer look at how things played out in 2016.

PNC Financial Services Group Inc. lifted its position in shares of Marriott International Inc (NASDAQ:MAR) by 207.7% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,000,670 shares of the company’s stock after bu

There have been some macroeconomic signs that America's housing boom is starting to show signs of fatigue, but those figures haven't really shown up in the earnings reports of most homebuilders. The one exception is Beazer Homes USA (NYSE:BZH). While most companies are still showing strong home

Sturm Ruger & Company Inc (NYSE:RGR) announced a quarterly dividend on Wednesday, August 1st, RTT News reports. Stockholders of record on Friday, August 17th will be paid a dividend of 0.34 per share on Friday, August 31st. This represents a $1.36 dividend on an annualized basis and a dividen